<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30103233</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1438-9010</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>13</Day>                    </PubDate>                </JournalIssue>                <Title>RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin</Title>                <ISOAbbreviation>Rofo</ISOAbbreviation>            </Journal>            <ArticleTitle>Higher Detection Rates of Biologically Aggressive Breast Cancers in Mammography Screening than in the Biennial Interval.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1055/a-0657-3970</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE"> Assessment of age group-dependent detection rates of invasive breast cancers among participants in mammography screening including the interval, classified into immunohistochemical subtypes indicating the intrinsic tumor aggressiveness.</AbstractText>                <AbstractText Label="MATERIALS UND METHODS" NlmCategory="UNASSIGNED"> The target population comprises women aged 50 - 69 years. All invasive breast cancers diagnosed in one screening (sc) unit during the implementation phase 1/2006 - 12/2010 or identified by the cancer registry during the biennial interval (iv) were categorized based on hormonal-receptor status (HR) and Her2-expression (Her2) into the following subtypes: a) HR+ Her2-, b) HR+ Her2 +, c) HR- Her2 + or d) HR- Her2- (triple-negative); Her2 + and triple-negative types were defined as aggressive. The calculated detection rates (DR, ‰) were based on 53 375 sc-examinations and for the interval on 52 887 sc-negative examinations.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS"> The DRs of all subtypes were higher in screening versus the interval: (a) 4.95 ‰ (n = 264) vs. 1.00 ‰ (n = 53); b) 0.92 ‰ (n = 49) vs. 0.25 ‰ (n = 13); c) 0.36 ‰ (n = 19) vs. 0.06 ‰ (n = 3); d) 0.39 ‰ (n = 21) vs. 0.19 ‰ (n = 10). 77.4 ‰ (89/115) of all aggressive breast cancers including the following 2-year interval were diagnosed by screening. The sum of the DR of aggressive cancers was 1.67 ‰ in screening and 0.49 ‰ in the interval; the corresponding DRs for women aged 60 - 69 years [sc: 2.24 ‰ (51/22 814), iv: 0.58 ‰ (13/22 536)] were higher than among women aged 50 - 59 years [sc: 1.24 ‰ (38/30 561), iv: 0.43 ‰ (13/30 351)].</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS"> Screening has the potential for earlier diagnosis of aggressive tumor types as its detection rate is about three-fold higher compared to the interval. Within the target group, participants aged 60 - 69 years are at risk based on absolute numbers. They show a nearly two-fold higher detection rate of Her2-positive or triple-negative tumors compared to the age group 50 - 59 years.</AbstractText>                <AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">  · Her2-positive and triple-negative detection rates are higher in screening than in the interval.. · 77 % of aggressive subtypes are diagnosed by screening, 23 % during the 2-year interval.. · The detection rate is highest among women aged 60 - 69 years in screening..</AbstractText>                <AbstractText Label="CITATION FORMAT" NlmCategory="UNASSIGNED">· Prange A, Bokhof B, Polzer P et al. Higher Detection Rates of Biologically Aggressive Breast Cancers in Mammography Screening than in the Biennial Interval. Fortschr Röntgenstr 2018; DOI: 10.1055/a-0657-3970.</AbstractText>                <CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Prange</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Clinical Radiology and Reference Center for Mammography Muenster, University of Muenster and University Hospital Muenster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Bokhof</LastName>                    <ForeName>Beate</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Clinical Radiology and Reference Center for Mammography Muenster, University of Muenster and University Hospital Muenster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Polzer</LastName>                    <ForeName>Philipp</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Clinical Radiology and Reference Center for Mammography Muenster, University of Muenster and University Hospital Muenster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Tio</LastName>                    <ForeName>Joke</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology and Obstetrics, University of Muenster and University Hospital Muenster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Radke</LastName>                    <ForeName>Isabel</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology and Obstetrics, University of Muenster and University Hospital Muenster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Heidinger</LastName>                    <ForeName>Oliver</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Registry of North Rhine-Westphalia, Bochum, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Heindel</LastName>                    <ForeName>Walter</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Clinical Radiology and Reference Center for Mammography Muenster, University of Muenster and University Hospital Muenster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="N">                    <LastName>Weigel</LastName>                    <ForeName>Stefanie</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Clinical Radiology and Reference Center for Mammography Muenster, University of Muenster and University Hospital Muenster, Germany.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <VernacularTitle>Höhere Detektionsraten biologisch aggressiver Mammakarzinome im Mammografie-Screening als im 2-jährigen Intervall.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Rofo</MedlineTA>            <NlmUniqueID>7507497</NlmUniqueID>            <ISSNLinking>1438-9010</ISSNLinking>        </MedlineJournalInfo>        <OtherAbstract Type="Publisher" Language="ger">            <AbstractText Label="ZIELSETZUNG" NlmCategory="UNASSIGNED"> Ermittlung der altersgruppenabhängigen Detektionsraten invasiver Mammakarzinome im Mammografie-Screening einschließlich des Intervalls, differenziert nach immunhistochemischer Subtypisierung als Parameter der intrinsischen Tumoraggressivität.</AbstractText>            <AbstractText Label="MATERIAL UND METHODE" NlmCategory="UNASSIGNED"> Die Zielgruppe sind 50 – 69-jährige Frauen. Alle in einer Screening-Einheit während der Implementierungsphase 1/2006 – 12/2010 in Screening (Sc)-Untersuchungen und im folgenden 2-jährigen Intervall (Iv) diagnostizierten invasiven Mammakarzinome wurden anhand des Hormonrezeptorstatus (HR) und der Her2-Expression (Her2) folgenden Subtypengruppen zugeordnet: a) HR+ Her2-, b) HR+ Her2 +, c) HR– Her2 + oder d) HR– Her2– (triple-negativ); Her2 + und triple-negativ wurden als aggressiv definiert. Die ermittelten Detektionsraten (DR, ‰) basierten auf 53 375 Sc-Untersuchungen und für das Intervall auf 52 887 Sc-negativen Untersuchungen.</AbstractText>            <AbstractText Label="ERGEBNISSE" NlmCategory="UNASSIGNED"> Die DR aller Subtypengruppen waren im Screening höher als im Intervall: (a) 4,95 ‰ (n = 264) vs. 1,00 ‰ (n = 53); b) 0,92 ‰ (n = 49) vs. 0,25 ‰ (n = 13); c) 0,36 ‰ (n = 19) vs. 0,06 ‰ (n = 3); d) 0,39‰ (n = 21) vs. 0,19‰ (n = 10). 77,4 ‰ (89/115) aller aggressiven Mammakarzinome einschließlich des folgenden 2-Jahresintervalls wurden im Screening diagnostiziert. Die Summe der DR aggressiver Karzinome betrug im Screening 1,67‰ und im Intervall 0,49 ‰; dabei lagen die DR bei den 60 – 69-Jährigen [Sc: 2,24 ‰ (51/22 814), Iv: 0,58‰ (13/22 536)] höher als bei den 50 – 59-Jährigen [Sc: 1,24‰ (38/30 561), Iv: 0,43‰ (13/30 351)].</AbstractText>            <AbstractText Label="SCHLUSSFOLGERUNG" NlmCategory="UNASSIGNED"> Screening hat das Potenzial einer Diagnosevorverlagerung aggressiver Tumorsubtypen bei einer etwa 3-fach höheren Detektionsrate als im Intervall. In der Zielgruppe bilden 60 – 69-Jährige bezüglich der absoluten Diagnosehäufigkeit eine Risikogruppe mit einer nahezu doppelten Detektionsrate Her2-positiver oder triple-negativer Tumoren im Vergleich zu 50 – 59-Jährigen.</AbstractText>            <AbstractText Label="KERNAUSSAGEN" NlmCategory="UNASSIGNED">  · Detektionsraten Her2-positiver und triple-negativer Mammakarzinome liegen im Screening höher als im Intervall.. · 77 % dieser aggressiven Subtypen werden im Screening diagnostiziert, 23 % im folgenden 2-Jahresintervall.. · Die höchste Detektionsrate aggressiver Mammakarzinome im Screening findet sich bei 60 – 69-Jährigen..</AbstractText>            <AbstractText Label="ZITIERWEISE" NlmCategory="UNASSIGNED">· Prange A, Bokhof B, Polzer P et al. Higher Detection Rates of Biologically Aggressive Breast Cancers in Mammography Screening than in the Biennial Interval. Fortschr Röntgenstr 2018; DOI: 10.1055/a-0657-3970.</AbstractText>        </OtherAbstract>        <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30103233</ArticleId>            <ArticleId IdType="doi">10.1055/a-0657-3970</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>